Recently,

“Opening Ceremony for Enterprises Settling at Chengdu Advanced Medical Science Center

& 2021 IPO Listing Practice Sharing Meeting for Bio-pharmaceutical Enterprises”

was held at Chengdu Advanced Medical Science Center.

On the site, 5 enterprises including Beiya, Saijing,

Origiant, Chuankang Ginkgo and Keruixin Pharmaceutical

settled at Chengdu Advanced Medical Science Center.

 

 

B I O T I A N F U

The 5 enterprises start business together

and cooperate in innovation to get through "the last one mile" for deliverable transformation.

—

 

A total of 5 enterprises start business intensively,

including Beiya, Saijing,

Origiant, Chuankang Ginkgo and Keruixin Pharmaceutical.

All of them are founded by professors from Sichuan University.

 

Phase I of Chengdu Advanced Medical Science Center

 

Origiant

Origiant was co-founded by the team of Prof. Yang Shengyong from State Key Laboratory of Biotherapy (SKLB), Sichuan University, and the listed company Chongqing Pharscin Pharmaceutical Co., Ltd. It plans to invest in original new drug development program targeting small molecule inhibitors of the cell NECROPTOSIS in CDHT and engages in Class I drug development business targeting small molecule inhibitors of the cell NECROPTOSIS.

 

 

Saijing

Saijing was founded by the team of Prof. Xu Liang from West China School of Pharmacy Sichuan University, and Jiangsu Yunyang Pharmaceutical Group Co., Ltd. It will invest in R&D projects of original new drugs, innovative preparations and generic drugs with high technology barriers. It plans to build a platform for synthetic chemistry, druggability evaluation and drug quality release related to core technologies, screen and develop 3-6 original small molecule new drugs in the fields of tumors and metabolism in the next 5 years.

 

 

Beiya

Beiya was founded under the leadership of Fan Yujiang, Deputy Director of National Biomaterials Engineering Research Center, Sichuan University. It is engaged in the use of advanced 3D printing digital manufacturing technology to achieve individualized precise repair of defects.

 

Chengdu Advanced Medical Science Center focuses on “innovation, R&D - achievement incubation - Industrialization implementation”, provides all-round one-stop services for projects and get through the "last mile" of R&D achievement transformation.

- Fan Yujiang, Head of Beiya

 

Phase II of Chengdu Advanced Medical Science Center

 

Since November 2018 the Management Committee of CDHT and Sichuan University

signed the agreement on

co-building of Chengdu Advanced Medical Science Center in November 2018,

the Center has focused on cell and gene therapy,

advanced technology and future medicine

to innovatively establish the school-local cooperation model of

"co-construction, co-management, sharing and co-service",

“PI+” deliverable transformation service model,

the first place to determine the ownership of technological deliverables

and the sharing model of “business partners”.

 

So far, Chengdu Advanced Medical Science Center has introduced 37 high-level R&D projects such as West China Biomedical Big Data Center, 12 transformation projects of professors from Sichuan University, and 16 major industry projects including West China headquarters of World Global 500 AstraZeneca. Besides, the Center attracts 2 academician talents, 8 national-level talents and nearly 2,000 technical talents.

 

B I O T I A N F U

Set up a corporate IPO exchange platform

CDHT promotes high-quality development of bio-pharmaceutical industry

—

 

Besides,

IPO listing practice sharing for bio-pharmaceutical enterprises was also held.

Multiple guests shared and interacted on

overseas financing and listing of bio-pharmaceutical enterprises.

 

 

 

Through this activity, we have learned about the latest policies of domestic and foreign capital markets and mastered key and difficult problems of IPO listing of bio-pharmaceutical enterprises. The activity has greatly helped us to make the best listing plan and financing plan and effectively enhance the comprehensive competitiveness and anti-risk ability of an enterprise.

- Yang Shengyong, Co-founder of Origiant

 

 

As the main base of Chengdu bio-pharmaceutical industry, CDHT has established the one-stop service model of "professional service + generic service" according to resource factor demands of enterprise R&D life cycle, providing three categories and 14 professional services from R&D to production and sales. Meanwhile, through cooperation with municipal platform companies, CDHT jointly launched 18 generic services in five categories including science and technology finance and entrepreneurship incubation.

 

 

In recent years, CDHT has regarded connecting multi-level capital market as an important support to achieve high-quality industrial development and set up a "green channel" of government services for the listing of bio-pharmaceutical enterprises. It better helps enterprises solve their financial problems, enables them to focus on innovative R&D, and helps CDHT to accelerate the construction of a biological industry ecosystem.

 

# Tianfu Life Science Park

Tianfu Life Science Park where Chengdu Advanced Medical Science Center is located is a national-level high-tech business incubator and also a well-known bio-pharmaceutical R&D innovation center and industrial incubation center in China.

 

 

Nearly 200 bio-pharmaceutical enterprises have settled in the Park. The park has successfully incubated and cultivated the first enterprise listed on the science and technology innovation board - HitGen, the enterprise listed on the Hong Kong Stock Exchange - Conmed Biosciences, and many other enterprises, becoming an epitome of the rapid development of bio-pharmaceutical enterprises in CDHT.

 

Next,

CDHT will focus on advantageous segments of bioindustry, and

continue to hold BIO-LINK investment and financing road show activities,

leverage the capital market for enterprise development,

continue to improve the quality and efficiency of services for the real economy,

facilitate the biological industry financial chain of CDHT to be strong and supplementary,

further driving the construction of bio-pharmaceutical industry ecosystem

and national life and health laboratory.

 

 

Source: CDHT